EXACT Therapeutics AS: Minutes of Annual General Meeting 2022

OSLO/LONDON, 8 June 2022: EXACT Therapeutics AS (“EXACT-Tx”, “the Company” Euronext Growth: EXTX) held its Annual General Meeting on June 8th 2022 at 10:30 CEST.

According to the record included as Appendix 1, 7,798,139 shares of a total of 29,992,167 issued shares and votes, corresponding to 26% of the total number of voting shares in the Company, were represented at the general meeting.

All proposed resolutions were approved.

Please find enclosed the minutes of the meeting including appendices.

ENDS

Appendices:
Minutes of the Annual General Meeting on the 8th of June 2022.

For more information, please contact: 

Per Walday, CEO
EXACT Therapeutics
Email: per.walday@exact-tx.com

Dominic Moreland, CFO
EXACT Therapeutics
Email: Dominic@exact-tx.com

About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drug targeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com

Forward looking statements
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.